Article
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis
11 Jan 2017
Abstract excerpt
Myasthenia gravis (MG) is a rare debilitating autoimmune neuromuscular disorder. Many studies have focused on the mechanism and treatment strategies of MG. However, the exact pathogenesis of MG and effective treatment strategies remain unclear. Recent studies have indicated that microRNAs (miRNAs or miRs) can regulate the pathological pathways of MG, suggesting their potential role in novel treatments. In the...
Topics
Join the communities discussing this publication.